Article info

Download PDFPDF

Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’

Authors

  1. Correspondence to Dr Jenny Devenport, F Hoffmann-La Roche AG, Basel 4053, Switzerland; jenny.devenport{at}roche.com
View Full Text

Citation

Pethoe-Schramm A, Devenport J, Reiss W
Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’

Publication history

  • Received June 19, 2020
  • Accepted June 23, 2020
  • First published July 31, 2020.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.